Acutaas Chemicals Ltd share price
Acutaas Chemicals Ltd (ACUTAAS) is a stock listed on India's exchanges (NSE & BSE). As of the latest filings, Acutaas Chemicals Ltd has a return on equity (ROE) of 24.00%, return on capital employed (ROCE) of 31.60%, a price-to-earnings (P/E) ratio of 73.80 and a debt-to-equity ratio of 0.01. On Traddx you can view its live price, interactive candlestick charts with 20/50/200-day moving averages and golden/death-cross detection, quarterly results, analyst price targets, peer comparison, and the smart-money signal — which star investors hold it and who is buying it on today's bulk/block deals tape.
Key fundamentals
Source: screener.in (NSE/BSE filings) · Fundamentals as of 02 Nov 2026 · figures from the latest annual & quarterly filings. Not investment advice.
Acutaas Chemicals Limited value chain — customers, suppliers & competitors
Acutaas Chemicals Limited is a research and development-driven manufacturer of specialty chemicals, supplying advanced pharmaceutical intermediates, active pharmaceutical ingredients, and agrochemical materials to global and domestic markets.
🛒 Customers — who buys from Acutaas Chemicals Limited
- Global Pharmaceutical and Agrochemical Companies — Advanced pharmaceutical intermediates and specialty chemical ingredients
⛓️ Suppliers — raw materials & inputs
- Basic chemical raw material suppliers — Petrochemical derivatives and basic chemical inputs
⚔️ Competitors — other sellers
- Lupin Limited — Competes in advanced pharmaceutical intermediates and API development.
- Marksans Pharma Limited — Competes in pharmaceutical formulations and related chemical requirements.
🔀 Other suppliers to its customers
- Other specialty chemical manufacturers — Global pharmaceutical firms often dual-source specialty intermediates from alternative chemical producers in China and Europe.
🤝 Peers that share its suppliers
- Other Indian Specialty Chemical Companies — Shares common upstream petrochemical and basic chemical feedstock suppliers.
This value-chain map is AI-researched from public sources; company links and any figures are estimates, not official company disclosures. Not investment advice.